Shenzhen YHLO Biotech Co., Ltd.

Equities

688575

CNE100005204

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. Other stock markets 10/04/2026			5-day change	1st Jan Change
14.85 ^CNY	+1.23%		+2.70%	+4.58%

03-17	Shenzhen YHLO Biotech receives notice of administrative penalty from regulator	RE
03-02	E-Health Now LLC announced that it has received funding from a group of investors	CI

Huamei Haolian Medical Technology Co., Ltd. announced that it has received funding from a group of investors

Published on 03/01/2026

S&P Capital IQ

SHENZHEN YHLO BIOTECH CO., LTD.

+1.23%

Huamei Haolian Medical Technology (Beijing) Co., Ltd. announced that it has received several hundred million RMB in round of funding co-led by new investors Efung Capital, Shenzhen YHLO Biotech Co., Ltd., returning investors Ventech China Ltd., Borchid Capital March 2, 2026. The transaction also included participation returning investors Suzhou Wujiang District City Investment Development Group Co.,Ltd, GSR Ventures Management Co. Ltd., Tongji Alumni Fund.

The company issued convertible preferred stock in the transaction.

Latest news about Shenzhen YHLO Biotech Co., Ltd.

03-17	Shenzhen YHLO Biotech receives notice of administrative penalty from regulator	RE
03-02	E-Health Now LLC announced that it has received funding from a group of investors	CI
03-01	Suzhou Haohai Medical Treatment Technology Co., Ltd. announced that it has received funding from a group of investors	CI
03-01	Huamei Haolian Medical Technology Co., Ltd. announced that it has received funding from a group of investors	CI
02-27	Shenzhen YHLO Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-07	YHLO Biotech Discloses 'Uncertainty' Stemming From Recent Partnership With Brain-Machine Starlink	MT
12-24	Shenzhen YHLO Biotech Subsidiary Gets Chinese Provincial-Level Approval for Two Diagnostic Kits	MT
12-16	Shenzhen YHLO Biotech Gets Chinese Provincial Regulator's Approval for Two Autoimmune Disease Testing Kits	MT
11-28	YHLO Biotech Gets Dutch Certification for HIV Kit	MT
11-26	YHLO Biotech Gets Guangdong Registrations for sST2 Test Kit, Microfluidic Analyzer	MT
11-20	Shenzhen YHLO Biotech Gets Guangdong Approval for Immunoassay Analyzer	MT
11-18	Shenzhen YHLO Biotech Gets Guangdong, China Regulatory Approval for Detection Kit	MT
11-07	YHLO Biotech Gets Registration Certificate for Human Chorionic Gonadotropin Kit	MT
29/10/25	Shenzhen YHLO Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
11/09/25	YHLO Biotech's Controlling Shareholder Trims Stake	MT

Chart Shenzhen YHLO Biotech Co., Ltd.

Duration

Period

688575: Dynamic Chart

Company Profile

Shenzhen YHLO Biotech Co Ltd is a China-based company principally engaged in the research and development, manufacture and sales of in-vitro diagnostic equipment and supporting reagents, as well as the agency sales of some non-self-produced medical device products. The Company's products are applied in autoimmunity, reproductive health, diabetes and infectious disease fields. The Company's main products include in-vitro diagnostic instruments and supporting reagents based on chemiluminescence, immunoblotting, enzyme-linked immunoassay, immunofluorescence chromatography and other methodologies. The Company distributes its products in domestic market and to overseas markets.

Employees

1,678

Sector

Medical Equipment, Supplies & Distribution

Calendar

04-29 - Earnings release - Annual 2025

More about the company